Pravastatin
| Evidence Level: L3 | Predicted Indications: 9 |
Table of Contents
Pravastatin: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia
One-Sentence Summary
Pravastatin is an HMG-CoA reductase inhibitor (statin) with a well-established history in treating hypercholesterolemia and reducing cardiovascular risk. The TxGNN model predicts it may also be effective for Homozygous Familial Hypercholesterolemia (HoFH), but the currently available evidence — 1 clinical trial (studying a different drug, alirocumab, in the same patient population) and 13 publications — is indirect and does not yet directly test pravastatin in this population.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypercholesterolemia / dyslipidemia (cardiovascular risk reduction) — official India label text not available (data gap) |
| Predicted New Indication | Homozygous Familial Hypercholesterolemia |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L3 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, pravastatin is a member of the statin class, and its efficacy in lowering LDL cholesterol and reducing cardiovascular risk in hypercholesterolemia has been well established; mechanistically it may be applicable to disorders of LDL metabolism such as familial hypercholesterolemia.
However, in Homozygous Familial Hypercholesterolemia specifically, patients have near-total absence of functional LDL receptors due to biallelic LDLR mutations. Since statins like pravastatin work primarily by upregulating hepatic LDL receptor expression, their effect is mechanistically limited in this population. In clinical practice, statins are typically used only as adjunct therapy alongside PCSK9 inhibitors or LDL apheresis rather than as monotherapy for HoFH.
The mechanistic rationale is therefore plausible but weaker than for general (heterozygous) familial hypercholesterolemia, where residual LDL receptor function allows statins to act more directly.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Evaluated alirocumab (not pravastatin) efficacy/safety on LDL-C in children and adolescents (8–17y) with HoFH on top of background lipid-lowering treatment. Included as population-relevant background evidence only — does not directly test pravastatin. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31696945 | 2019 | Systematic Review | Cochrane Database Syst Rev | Cochrane review of statin use in children with familial hypercholesterolemia, covering both heterozygous and homozygous forms |
| 28685504 | 2017 | Systematic Review | Cochrane Database Syst Rev | Earlier version of the same Cochrane review on statins for pediatric familial hypercholesterolemia |
| 28437620 | 2017 | Guideline | Endocr Pract | AACE/ACE guideline for management of dyslipidemia and cardiovascular disease prevention |
| 12269853 | 2002 | Review | Drugs | Review of rosuvastatin noting comparative lipid-lowering performance versus pravastatin and other statins |
| 14727947 | 2003 | Review | Am J Cardiovasc Drugs | Review of ezetimibe as adjunct cholesterol-lowering therapy |
| 15531000 | 2004 | Review | Clin Ther | Review of rosuvastatin management of hyperlipidemia, including homozygous FH indication context |
| 14647533 | 2003 | Review | Cardiovasc Drug Rev | Review of ezetimibe as a cholesterol absorption inhibitor for combination therapy |
| 9793596 | 1998 | Review | Ann Pharmacother | Review of atorvastatin efficacy/safety in primary hypercholesterolemia and mixed dyslipidemia |
| 9129869 | 1997 | Review | Drugs | Pharmacology and therapeutic potential review of atorvastatin in hyperlipidemias |
| 31358055 | 2019 | Basic Science | Stem Cell Res Ther | iPSC-derived hepatocyte model of familial hypercholesterolemia used for LDLR gene correction studies |
India Market Information
Pravastatin is currently not marketed in this jurisdiction (0 registrations on file). No license or product registration records are available to summarize.
Safety Considerations
- Drug Interactions: A total of 239 drug-drug interactions were identified. Notable moderate-level interactions include: Metronidazole, Clarithromycin, Eluxadoline, Naltrexone, Pectin, Rosuvastatin, Simvastatin, and Tinidazole. A larger number of interactions (e.g., Calcitriol, Acarbose, Sucralfate, Palonosetron, Rosiglitazone, Vancomycin, Lactulose, Triamcinolone, Prednisone, Nystatin, Nateglinide, Scopolamine) are flagged with unknown severity level and require individual clinical evaluation.
Official warning and contraindication text is not available in this evidence pack (data gap) — please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is currently indirect — the only registered clinical trial studies a different drug (alirocumab) in the HoFH population, and no pravastatin-specific efficacy trial in HoFH exists. Combined with a blocking data gap on official safety labeling (warnings/contraindications), the candidate cannot yet complete a preliminary safety assessment (S1) and does not meet the bar to proceed.
To proceed, the following is needed:
- Official TFDA/India label warnings and contraindications (currently a blocking data gap, DG001)
- Confirmed mechanism of action data (DG002)
- Pravastatin-specific clinical or observational evidence in HoFH patients (current trial evidence is for alirocumab, not pravastatin)
- Clarification on whether pravastatin is intended as monotherapy or adjunct to PCSK9 inhibitors/apheresis in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.